The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.
Arcadia Consumer Healthcare Inc., (formerly Kramer Laboratories Inc.) a recognized leader in the consumer healthcare industry, announced that the company completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.
Takeda Pharmaceutical Co. Ltd. will sell some over-the-counter and prescription drugs to Germany’s Stada Arzneimittel AG for a total value of $660 million.
An independent expert panel to the U.S. FDA recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
French drugs and healthcare group Sanofi signed a rights deal with Roche for Tamiflu in the United States.
Aspen Pharmacare said Mylan NV exercised an option to buy the South African drugmaker’s portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).
The Consumer Healthcare Products Association (CHPA) released a study – “Value of OTC Medicines to the U.S. Healthcare System” – finding on average that each dollar spent on over-the-counter medicines saves the U.S. healthcare system approximately $7.20, totaling nearly $146 billion in annual savings.
The U.S. Food and Drug Administration said two of the 16 currently used main chemical ingredients in over-the-counter sunscreen products are considered safe, as part of a proposal aimed at improving the safety and quality of sunscreen products sold without prescription in the United States.
GlaxoSmithKline bolstered the company’s cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Merck KGaA for the rights to a next-generation immunotherapy.